Barbara McAneny, MD, MACP, FASCO, Chief Executive Officer, New Mexico Cancer Center, Oncology Hematology Consultants

Kimberly Peairs, MD, Vice Chair for Ambulatory Operations, Department of Medicine; Associate Professor of Medicine, The Johns Hopkins Hospital, The Sidney Kimmel Comprehensive Cancer Center

Lauren Wallner, PhD, MPH, Assistant Professor, Department of Medicine and Department of Epidemiology; Adjunct Investigator, University of Michigan

Once a comprehensive cancer survivorship plan is developed by oncology, it is widely accepted that clinical management of the survivorship plan is routinely assumed by the patient’s primary care physician (PCP). But is that the best—and most cost effective—model to deliver cancer survivorship care? And does this model take into account patient perspectives or preferences? Learn what research has found, including the features of a well-designed survivorship communication process. Then hear different models for delivering comprehensive cancer survivorship care, from embedding primary care in oncology to the reverse—embedding oncology in primary care.

Jennifer Urban, Partner, Foley & Lardner

James Hamrick, MD, MPH, Vice President, Clinical Oncology, Flatiron Health

Nick Accomando, Compliance and Privacy Officer, Flatiron Health

Emily Wampfler, MS, MBA, Senior Director of Product Management, Mayo Clinic

Cary Gross, MD, Professor of Medicine and Director of the Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine; co-author, A New Deal for Cancer Care: Lessons From a 50 Year War

Learn how the rise in cancer costs is attributable to a “cancer cost trifecta”—more cancers are being diagnosed, there is a higher utilization of cancer-related care, and there are now more expensive testing and treatment options available. Hear how a range of policy initiatives and reforms could help realign the interests of scientists, providers, policy makers, and industry in order to prioritize patients and the public and reduce cancer costs. These include ramping up tobacco control efforts, supporting evidence-based prevention strategies (e.g., cervical cancer vaccination and colorectal cancer screening), and using payment reform to encourage high-value care. To reduce prescription drug spending, Dr. Gross supports the following measures: (1) expediting generic and biosimilar agents; (2) decoupling patient deductibles and co-pays from the cost of cancer care; (3) basing prices for new and existing therapies on their clinical benefits (“value-based pricing”); and (4) decoupling payer reimbursement from the U.S. Food and Drug Administration approval process.

Mike Kolodziej, MD, Vice President and Chief Innovation Officer, ADVI Health, LLC (Moderator)

Lee Blansett, Principal, Proximity Health

Harlan Levine, MD, President, Strategy and Business Ventures, City of Hope National Medical Center

Paul Martino, Co-Founder and Chief Growth Officer, VillageMD

Brian Wydra, Senior Vice President, Oncology & Infusion, OptumCare

Hear an overview of industry reconfiguration and consolidation trends and its impact on oncology. Learn the value propositions of three different business models and how each improves cancer care services in terms of access, quality, outcomes, and cost. Then listen to a panel discussion of how these other models may impact the delivery of cancer care going forward, followed by an interactive audience Q&A.

Adria Warren, Partner, Foley & Lardner

Tynan Kugler, CVA, Principal, PYA

Phil Watts, General Counsel, OneOncology

Oncology transactions are often complex and require keen attention to numerous regulatory, compliance, operational, and financial issues. From deal structure to due diligence, this session will highlight key consolidation considerations, including compliance with applicable laws and identification of risk area as well as offer practical guidance to navigating the factors critical to a successful partnership.

Rebekkah Schear, MIA, Associate Director, Patient Experience; Co-Founder, Imagination Lab for Clinical Innovation, The University of Texas Dell Medical School, LIVESTRONG Cancer Institutes

Robin Richardson, MA, Assistant Director of Care Delivery Transformation & Community Engagement; Co-Founder, Imagination Lab for Clinical Innovation, The University of Texas Dell Medical School, LIVESTRONG Cancer Institutes

How do I know if my cancer program is improving patient outcomes and quality of life? How can we assess if new models of care are working? Join us for this session and learn about the robust impact, quality, and evaluation strategy Livestrong Cancer Institutes developed to measure its new model of person-centered cancer care. During this interactive discussion, presenters share the nuts and bolts of their evaluation, including a patient-reported outcome (PRO) strategy for measuring patient experiences (PREMs); how to measure clinical outcomes, access to care, and care coordination; and how to measure cancer care provider experience and attitudes. Then do a deep dive into how their team built and deployed a massive chart abstraction to assess utilization of supportive care services by patients; development and deployment of a patient experience survey; how to design a study for qualitative data collection from patients; and how to develop and field a provider experience survey to evaluate whether the provider team is happy, if their work is meaningful, and measure their level of resilience.

Barry Russo, MBA, Chief Executive Officer, The Center for Cancer & Blood Disorders (Moderator)
Ed Rodgers, Director of Network Development, ClinicalPath, Elsevier
Peter Webner, General Manager, Breast Oncology US, GE Healthcare
Shawn Huda, Director of Product Management, Flatiron Health
Rebecca Maniago, PharmD, Associate Director, Clinical Oncology, Flatiron Health
Amila Patel, PharmD, BCOP, Chief Clinical Officer, Navigating Cancer
Ruthvik Malladi, PharmD, Associate Director, Precision Medicine, Blueprint Medicines
Tanya Park, Director, Innovation Solutions, Cardinal Health

Amy Gordon Franzen, Vice President of Operations, Therapies Business Lead, Tempus Labs, Inc.

Mark Liu, Director, Strategic Initiatives, Oncology Service Line, Mount Sinai Health System & Tisch Cancer Institute

This inpatient oncology unit used Activity Measure for Post-Acute Care scores to quantify mobility and then develop team-based, multidisciplinary plans of care in collaboration with physical therapy, nursing, and a mobility aide—a medical assistant with rehabilitation training. Patients were mobilized twice per day, seven days per week. Staff evaluated the effects of the mobility aide program on quality of care and healthcare utilization and observed significant improvement in both. Outcomes across nearly 1,000 patients include: a 6% reduction in excess days; a reduction of readmission rates from 25% to 19%; three-quarters of patients (76%) maintained or improved their mobility score; and improved patient satisfaction—patient willingness to recommend the hospital increased from 63% to 91%.

Candice Roth, MSN, RN, CENP, Assistant Vice President, Central Region Operations, Nursing, Quality, Outreach, & Disparities, Atrium Health, Levine Cancer Institute
Melynda Ozan, Consumer Health Librarian, Atrium Health, Levine Cancer Institute

Levine Cancer Institute successfully developed tools and methods to encourage shared decision-making across its network of more than 25 regional sites. Learn how this cancer institute built a standardized treatment platform (Electronically Accessible Pathways, or EAPathways), so all clinicians are using the same evidence-based guidelines, treatment updates, and clinical trials. This ensures that patients across more than 25 clinic locations receive the most consistent, high-quality care possible. Then, in 2017, Levine Cancer Institute hired a consumer health librarian to create a digital library of patient education handouts, including links to approved cancer information websites, which are available to all clinicians and staff through a Microsoft SharePoint site. This health librarian reviews all patient-facing information—including marketing brochures, new visitor policies, and patient education—to ensure materials are written at an appropriate reading level. The health librarian also sits on the Patient and Family Advisory Council, which is often involved in the development of patient resources and chairs the Oncology Patient Education Committee. To further improve shared decision making, Levine Cancer Institute uses a care alignment tool (CAT) to document clinician-patient discussions about goals of care in the patient’s chart for use in advanced care planning. The CAT includes questions that help identify patients' fears or concerns for the future, important goals, and preferences related to using sustaining measures at the end of life.

Mark Sobczak, MD, FACR, Medical Director, Radiation Oncology, Fox Chase Cancer Center
John Hennessey, MBA, CMPE, Senior Vice President, Strategist, Valuate Health Consultancy
Andrew Hertler, MD, Chief Medical Officer, New Century Health
Ira Klein, MD, MBA, FACP, Vice President, Medical Affairs & Payer Relations, Tempus Labs
Lalan Wilfong, MD, Vice President, Payer Relations and Practice Transformation, The US Oncology Network, McKesson

A moderated panel discussion about how current prior authorization processes impact cancer care delivery. Hear four stakeholder perspectives, starting with the emotional effect that prior authorizations—and associated treatment denials and delays—have on patients. Next, learn how burdensome prior authorization requirements are impacting providers, increasing workload and interfering in treatment decisions. Listen to the payer perspective and what is driving the increase in prior authorizations. Finally, learn the role that pathway intermediaries can play in streamlining—or even eliminating—prior authorizations.

Nina Chavez, MBA, FACMPE, Vice President, Value Based Care, Practice Solutions & Transformation, Flatiron Health (Moderator)
Laurie Travisano, Senior Director of Provider Solutions, Annexus Health
Mark Alwardt, Vice President, Medically Integrated Dispensing, The US Oncology Network, McKesson
Joe Versino, National Sales Director, LeanTaaS
Melissa McCain, MPPM, Director, Consumer Access Practice, The Chartis Group
Kelley D. Simpson, MBA, Director, Chartis Oncology Solutions, The Chartis Group

Open to all AMCCBS Virtual Attendees and Delegate Representatives of Cancer Member Programs.

Harlan Levine, MD, President, Strategy and Business Ventures, City of Hope National Medical Center

Cancer care is a complex—and often controversial—topic, with multiple stakeholders that view “value” through many different lenses. Hear what value in cancer care means to patients and their caregivers and how this meaning is usually different for payers and employers. Then consider how we define value in oncology reflects on us as a society. Strategize how these different perspectives fit together to yield a value equation that considers outcomes, patient experience, cost, and time…and yet it is not enough. Each stakeholder brings their own perspective to the relative value of these variables, resulting in solutions that address some issues while creating new ones. Hear about the role you can play in defining oncology value going forward, and in so doing, help drive to a better—and more equitable—cancer care delivery system.

Krista Nelson, MSW, LCSW, OSW-C, FAOSW, Program Manager of Quality & Research, Cancer Support Services and Compassion, Providence Health & Services

Jennifer Bires, MSW, LCSW, OSW-C, Executive Director, Life with Cancer and Patient Experience, Inova Schar Cancer Institute

Al B. Benson III, MD, FACP, FASCO, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center at Northwestern Medicine

Courtney Bitz, MSW, LCSW, OSW-C, Director of Clinical Social Work and Spiritual Care, Department of Supportive Care Medicine, City of Hope

Olalekan Ajayi, PharmD, MBA, Chief Operating Officer, Highlands Oncology Group, PA

The delivery of high-impact comprehensive cancer care services requires innovative care models with demonstrable return on investment (ROI). To help support this effort, hear an update about the ACCC 

Comprehensive Cancer Care Services Survey, designed to help explain benchmarking for and barriers to comprehensive cancer care, including lack of sufficient reimbursement, staffing, and budget. Then learn about the development of two new ACCC tools, Making the Business Case for Hiring an Oncology Social Worker and Making the Business Case for Hiring an Oncology Pharmacist, including how to leverage these tools to demonstrate ROI to hospital and practice leadership to help grow and support your cancer care team, expand your service line offerings, and improve the care you provide to patients with cancer and their families.

Alexis Finkelberg Bortniker, JD, Partner, Foley & Lardner

Ira Klein, MD, MBA, FACP, Vice President, Medical Affairs & Payer Relations, Tempus Labs

Deirdre Saulet, PhD, Expert Partner, Advisory Board Company

James Hamrick, MD, MPH, Vice President, Clinical Oncology, Flatiron Health

Nate Walcker, MBA, Chief Executive Officer, Florida Cancer Specialists & Research Institute

Steve D’Amato, BScPharm, Founding Partner, Scientia Pharmacy Advisors, LLC

John Hennessey, MBA, CMPE, Senior Vice President, Strategist, Valuate Health Consultancy

Deirdre Saulet, PhD, Expert Partner, Advisory Board Company

Bhavesh Shah, RPh, BCOP, Associate Chief Pharmacy Officer, Specialty and Hematology Oncology Pharmacy, Boston Medical Center

Joe Alvarnas, MD, Vice President of Government Affairs; Chief Clinical Advisor, AccessHope; Professor, Department of Hematology & Hematopoietic Cell Transplant, City of Hope National Medical Center

Alexis Finkelberg Bortniker, JD, Partner, Foley & Lardner

Providing healthcare for cancer is different than for any other disease. Cancer is now recognized not as one condition, but as multiple conditions. With genomic sequencing technology, cancer may soon be viewed as potentially hundreds of conditions. In 2021, the California State Assembly unanimously passed the Cancer Patients Bill—the first of its kind in the nation—which calls for six rights that every cancer patient in California should have. Access and equity are key components across these six rights, and this session will focus on grounded approaches to moving access and equity forward in meaningful ways. Creative solutioning includes establishing community-academic collaborations that are easily scaled and that ensure patients receive treatment in the communities where they live and developing care-focused strategies in partnership with employers. Hear patient stories, join the discussion, and return with ideas on how your cancer program or practice can work with your state legislators to improve the care of patients with cancer in your community.